The FDA has issued a series of regulatory updates in recent weeks spanning gene therapy, drug approvals, clinical trial oversight and compounding policy, reflecting a broader push to accelerate innovation while tightening compliance.
Here are five recent FDA developments:
1. Gene therapy push expands with new guidance, policy proposals
The FDA issued draft guidance on April 14 outlining safety standards for genome editing therapies, including recommendations for evaluating off-target risks using next-generation sequencing. The agency also proposed broader policy changes in its fiscal 2027 budget, including a new clinical trial notification pathway and an abbreviated licensure pathway for biologics to accelerate development and reduce regulatory burden.
2. FDA targets clinical trial transparency gaps
The agency has contacted more than 2,200 sponsors and researchers to submit required results to ClinicalTrials.gov, tied to more than 3,000 trials, according to an April 13 news release. An internal analysis found 29.6% of studies likely subject to reporting requirements have no results posted, raising concerns about incomplete safety and efficacy data for clinicians and health systems.
3. Oversight tightens across high-demand drug categories
The FDA said pharmacies must stop compounding GLP-1 drugs once branded versions are no longer in shortage, warning of enforcement action after issuing 30 warning letters tied to misleading claims. Separately, the agency said it is continuing a safety study on mifepristone, with further analysis pending as legal challenges over access continue.
4. New approvals expand treatment options
The FDA approved the first generic versions of Farxiga (dapagliflozin) for Type 2 diabetes and heart failure risk reduction, and cleared a higher-dose Spinraza (nusinersen) regimen for spinal muscular atrophy, which showed improved motor function in infants.
5. Leadership changes under consideration
The Trump administration is considering appointing Houman Hemmati, MD, PhD, to lead the FDA’s Center for Biologics Evaluation and Research as current Director Vinay Prasad, MD, prepares to depart at the end of April.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
